FDA Safety Communication: Pradaxa
The US Food and Drug Administration (FDA) is informing healthcare professionals and the public that the blood thinner (anticoagulant) Pradaxa ( dabigatran etexilate mesylate ) should not be used to prevent stroke or blood clots (major thromboembolic events) in patients with mechanical heart valves, also known as mechanical prosthetic heart valves.
Pradaxa Linked to Heart Attack Risk
Blood thinner dabigatran ( Pradaxa ), approved in 2010 to prevent stroke in patients with atrial fibrillation, a common heart arrhythmia, is linked to an increased risk of heart attack, a new trial suggests.
Blood Thinner Pradaxa May Lead to Bleeding
U.S. Food and Drug Administration officials are taking a second look at blood thinning drug Pradaxa ( dabigatran etexilate mesylate ) after reports of serious, potentially fatal, bleeding.
FDA Drug Safety Communication: Pradaxa
The U.S. Food and Drug Administration (FDA) is alerting the public to important storage and handling requirements for Pradaxa ( dabigatran etexilate mesylate ) capsules.